Low-dose maraviroc, an antiretroviral dru... - Cure Parkinson's

Cure Parkinson's

25,521 members26,841 posts

Low-dose maraviroc, an antiretroviral drug, attenuates the infiltration of T cells into the CNS and protects the nigrostriatum...2019

Bolt_Upright profile image
17 Replies

Low-dose maraviroc, an antiretroviral drug, attenuates the infiltration of T cells into the CNS and protects the nigrostriatum in hemiparkinsonian monkeys ncbi.nlm.nih.gov/labs/pmc/a...

"Abstract

Parkinson’s disease (PD) is the most common neurodegenerative movement disorder in humans. Despite intense investigation, no effective therapy is available to stop the progression of this disease. It is becoming clear that both innate and adaptive immune responses are active in PD. Accordingly, we have reported marked increase in RANTES (regulated on activation, normal T cell expressed and secreted) and eotaxin, chemokines that are involved in T cell trafficking, in vivo in the substantia nigra (SN) and the serum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated hemiparkinsonian monkeys. Since RANTES and eotaxin share a common receptor CCR5, we examined the efficacy of maraviroc, an inhibitor of CCR5 and an FDA-approved drug against HIV infection, in hemiparkinsonian rhesus monkeys. First, we found glial limitans injury, loss of GFAP immunostaining and infiltration of T cells across the endothelial monolayer in SN of hemiparkinsonian monkeys. However, oral administration of low dose of maraviroc protected glia limitans partially, maintained the integrity of endothelial monolayer, reduced the infiltration of T cells, attenuated neuroinflammation, and decreased α-synucleinopathy in the SN. Accordingly, maraviroc treatment also protected both the nigrostriatal axis and neurotransmitters, and improved motor functions in hemiparkinsonian monkeys. These results suggest that low-dose maraviroc and other CCR5 antagonists may be helpful for PD patients."

Written by
Bolt_Upright profile image
Bolt_Upright
To view profiles and participate in discussions please or .
Read more about...
17 Replies
park_bear profile image
park_bear

Refreshing to find a study done correctly:

" Monkeys displaying hemiparkinsonian symptoms 7 d after the first intracarotid injection were included in the study. Therefore, hemiparkinsonian monkeys were randomized and one group of hemiparkinsonian monkeys (n=4) were treated with maraviroc (1.0 mg/kg body wt/d) orally for 30 d through banana starting from 7 d of MPTP injection (Fig. 1). The control group of hemiparkinsonian monkeys (n=4) received only banana as vehicle."

This is an HIV antiretroviral. Cost is $500 and up monthly at the recommended dosage. Will check what dosage this trial amounts to for humans.

I may take a deeper look at this.

in reply to park_bear

This drug is used for HIV. I know only what I have read this evening. But what about Montelukast? Better safety and more widely used and more accessible. Have you ruled that one out? And it can be taken with Ambroxol bc in Europe it is sometimes combined? Just wondering if the interest in this antiviral Maraviroc is because you have ruled out Montelukast and Ambroxol?

Bolt_Upright profile image
Bolt_Upright in reply to

maraviroc is an anti-retroviral drug. Acyclovir and Valcyclovir are cheaper alternatives in the same ballpark.

They are trialing Valcyclovir for AD.

A role for viral infections in Parkinson’s etiology? portlandpress.com/neuronals...

in reply to Bolt_Upright

Herpes Virus Neurodegeneration

This applies to PD too from what I have read 67% of the population has it

statnews.com/2020/05/06/res...

Bolt_Upright profile image
Bolt_Upright in reply to

Yakult probiotic lowers titers against EBV (90% prevalence). I need to make some Yakult Yogurt today. Acyclovir and Yakult, locked into my stack.

in reply to Bolt_Upright

“Lowers titers”. New to me. Lowers the expression of Epstein bar virus? Wow

Herpes causes ALZ? Oral which is so common! Wow.

So acyclovir taken on an ongoing basis?

ncbi.nlm.nih.gov/labs/pmc/a...

park_bear profile image
park_bear in reply to

There is a huge noise to signal ratio of invalid versus valid studies. Valid studies that demonstrate improvement of the underlying Parkinson's disease condition are rare. Any such study gets my attention.

It is not a question of this substance versus some other substance. The question is what is the risk and cost/benefit situation for each substance independently.

I have not ruled out montelukast although I have some concern about adverse effects.

in reply to park_bear

Understood and appreciated. There is a plethora of “anti inflammatory antioxidant” choices. Antiviral is a new target for me that is possibly exciting to use with the aforementioned anti inflammatory antioxidants.

park_bear profile image
park_bear in reply to

In this case effectiveness is not due to blocking a virus.

in reply to park_bear

I thought it suppresses it

I will do my homework

park_bear profile image
park_bear in reply to

Right here in the abstract. It blocks a receptor also used by the HIV virus but in this case used by the immune system as originally designed by evolution:

"Since RANTES and eotaxin share a common receptor CCR5, we examined the efficacy of maraviroc, an inhibitor of CCR5"

in reply to park_bear

I’m just trying to priorities how I approach this. Antiviral seems like a great new target

Bolt_Upright profile image
Bolt_Upright in reply to

Effect of montelukast in experimental model of Parkinson’s disease 2018 sciencedirect.com/science/a...

"Abstract

Despite the availability of many drugs offering symptomatic relief in Parkinson’s disease, there are no drugs available offering neuroprotective effect. Hence, it was decided to evaluate the neuroprotective effect of montelukast, an anti-inflammatory drug, in rotenone induced model of Parkinson’s disease in rats. Forty eight male wistar rats were randomly divided into three groups. Group 1: Vehicle control, Group 2: Montelukast 5 mg/kg, Group 3: Montelukast 10 mg/kg. All the groups received rotenone 2.5 mg/kg intraperitoneally for 10 days as a disease inducing agent. The study drug montelukast was administered to respective groups orally from day 11 to day 24. On day 25, 24 h after 14 days of study drug administration, the rats were subjected to open field test, rota rod test and catalepsy test. Brain samples of rats from each group were collected for Malondialdehyde(MDA), Glutathione(GSH) and TNFα analysis. In the open field test both the doses of montelukast showed significant increase in the locomotor activity and also decreased the immobility time compared to vehicle (p < 0.05). In rotarod test, montelukast 5 mg/kg and 10 mg/kg showed significant increase in the time to fall, compared to vehicle (p < 0.05). In catalepsy test, both doses of montelukast significantly decreased the retraction time compared to vehicle(p < 0.05). The brain MDA levels were decreased and GSH levels were found to be higher in the two montelukast groups compared to vehicle (p < 0.05). TNFα levels too were decreased significantly on montelukast administration. Montelukast showed potential neuroprotective effect by virtue of its anti-oxidant and anti-inflammatory actions."

Biohacker2020 profile image
Biohacker2020 in reply to park_bear

Price has gone done quite a bit. It’s being used for long Covid also. Look up Dr Bruce Patterson. I take it…but stopped temporarily w pros and cons. My dose is too high for my sensitivity level.

Bolt_Upright profile image
Bolt_Upright in reply to Biohacker2020

Very interesting. Thanks!

park_bear profile image
park_bear

Interestingly the corresponding author for this study, Kalipada Pahan, Ph.D., was also the lead investigator for the cinnamon study that I cited in my report on cinnamon.

Biohacker2020 profile image
Biohacker2020

price of Maraviroc has gone down significantly and is being used by doctors for long covid protocol also. The dose I’m taking is too high and working on lowering it. Trying to see if it helps w my cognitive decline and other CNS symptoms. It has helped w my IBD also.

You may also like...

Add Idebenone Back to my Stack?

the M1 to M2 phenotype in LPS-activated BV2 cells and the MPTP induced PD model. Mechanistically,...

Low White Blood Cell Counts May Indicate Early Stages of Parkinson’s

blood test showed a low WBC so I went to Doctor Google and: Low White Blood Cell Counts May Indicate

Parkinson disease risks: correctly identifying environmental factors for a chronic disease

examined the risk of PD associated with medications commonly used to treat benign prostatic...

Methylphenidate for \"Parkinson's\"

Parkinson’s patients [9]. Additionally, MPD provides protection from the behavioral and...

Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo 2014

signaling pathways. Lastly, ar-turmerone protected hippocampal HT-22 cells from indirect neuronal...